ixazomib
Selected indexed studies
- Ixazomib. (, 2006) [PMID:29999909]
- Ixazomib. (, 2012) [PMID:31643334]
- Ixazomib - the first oral proteasome inhibitor. (Leuk Lymphoma, 2019) [PMID:30614337]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ixazomib. (2006) pubmed
- Ixazomib. (2012) pubmed
- Ixazomib - the first oral proteasome inhibitor. (2019) pubmed
- Ixazomib. (2026) pubmed
- Ixazomib for the treatment of multiple myeloma. (2018) pubmed
- Ixazomib: First Global Approval. (2016) pubmed
- Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis. (2022) pubmed
- Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. (2021) pubmed
- Ixazomib-induced angioedema. (2025) pubmed
- PMID:40080617 (2023) pubmed